Radioactive 'Smart Bomb' targets Hard-to-Treat prostate cancer
NCT ID NCT05114746
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a radioactive drug called 177Lu-PSMA-617 in 94 Japanese men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The drug seeks out and delivers radiation directly to cancer cells. Researchers measured how well it shrank tumors and how safe it was. The goal is to offer a new treatment option for this aggressive form of prostate cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
177Lu-PSMA-617 (a radioactive drug that targets prostate cancer cells)
What this could lead to
If successful, this could provide a new treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong
This is a small, early-phase study (Phase 2) with no comparison group, so results may not confirm effectiveness. Radioactive drugs can cause side effects like dry mouth, fatigue, and low blood counts.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Kashiwa, Chiba, 277-8577, Japan
-
Novartis Investigative Site
Sapporo, Hokkaido, 060-8648, Japan
-
Novartis Investigative Site
Kobe, Hyōgo, 6500047, Japan
-
Novartis Investigative Site
Yokohama, Kanagawa, 236-0004, Japan
-
Novartis Investigative Site
Chiba, 260-8717, Japan
-
Novartis Investigative Site
Fukushima, 9601295, Japan
-
Novartis Investigative Site
Ishikawa, 9208641, Japan
-
Novartis Investigative Site
Kyoto, 6068507, Japan